Proof-of-concept is provided in clinical studies with the IL-33 antibody etokimab, and with the ST2 antibody astegolimab showing improvement in patients with atopic dermatitis [75], a peanut allergy [76], or severe asthma [77]. Here, IL33 is linked to peanut allergic reaction.